No black box warning on record for Ipratroprium Bromide

As of the latest FDA labeling reviewed, Ipratroprium Bromide (IPRATROPRIUM BROMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Ipratroprium Bromide medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS: Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. If such a reaction occurs, therapy with Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) should be stopped at once and alternative treatment should be considered.

No black box warning on record for Ipratroprium Bromide

Other warnings & precautions

WARNINGS: Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. If such a reaction occurs, therapy with Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) should be stopped at once and alternative treatment should be considered.

Ipratroprium Bromide Black Box Warning

No black box warning on record for Ipratroprium Bromide

Other warnings & precautions

Ipratroprium Bromide Black Box Warning

No black box warning on record for Ipratroprium Bromide

Other warnings & precautions